BT5528

Phase 2

BICYCLE THERAPEUTICS PLC (BCYC)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

BCYCPhase 2$253M

BT5528 Phase 2 Est. Readout

BT5528• Advanced Solid Tumor Historically Known for High EphA2 Expression288

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Advanced Solid Tumor Historically Known for High EphA2 Expression

View Full Landscape

Drug Information

Target Indication

Advanced Solid Tumor Historically Known for High EphA2 Expression

Clinical Trial

NCT04180371

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BCYC

BICYCLE THERAPEUTICS PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Gemcitabine + cisplatin Or carboplatinPhase 3

Metastatic Urothelial Cancer

BT8009Phase 3

Urinary Bladder Neoplasm

Zelenectide pevedotinPhase 2

Non-Small Cell Lung Cancer

Zelenectide pevedotin (BT8009)Phase 2

Non-Small Cell Lung Cancer

nuzefatide pevedotin (BT5528)Phase 2

Pancreatic Ductal Adenocarcinoma (PDAC)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts